

# Interview Summary

Application No.	10/521,902	Examiner	D. Margaret Seaman
Applicant(s)	BARNHAM ET AL.	Art Unit	1625

All participants (applicant, applicant's representative, PTO personnel):

(1) D. Margaret Seaman

(2) Mark Cohen

Date of interview: 25 March 2008

Type: a) ☐ Telephonic b) ☐ Video Conference  
c) ☒ Personal [copy given to: 1) ☐ applicant 2) ☒ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☐ No

If Yes, brief description: \_\_\_\_\_

Claim(s) discussed: \_\_\_\_\_

Identification of prior art discussed: \_\_\_\_\_

Agreement with respect to the claims f) ☒ was reached. g) ☐ was not reached. h) ☐ N/A.

Substance of interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Rejections of record were discussed. 112-1st paragraph for solvate/hydrate...Applicant will provide declaration showing possession of hydrate/solvate. This will overcome this rejection. Rejection of 112, 1st for enablement for R3 and R' being other than H...Claim 30 page 3 lines 2-3 show the substituents enabled. This will overcome this rejection. 102 rejection for Carissiml will be withdrawn due to the R2 not being NHAc. Applicant will amend the claims around the Kacens and Vaidya art for 102. 103 Rejection will be overcome by showing of comparative data of closest prior art to closest claimed invention.